Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 3/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
| ▸ | GGT1 | P19440 | 4/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25345631 | 1.00 | GFPT1 (0.52) | GFPT1SLC7A5CASRGRIK1PTGS1 | |
| SCHEMBL542282 | 1.00 | GFPT1 (0.52) | GFPT1SLC7A5CASRGRIK1PTGS1 | |
| SCHEMBL1768739 | 0.84 | CASR (0.45) | GFPT1SLC7A5CASR | |
| SCHEMBL1768743 | 0.84 | CASR (0.45) | GFPT1SLC7A5CASR | |
| SCHEMBL28387960 | 0.83 | KDM4E (0.39) | GFPT1CASR | |
| SCHEMBL10280376 | 0.82 | GFPT1 (0.49) | GFPT1SLC7A5CASRGRIK1PTGS1 | |
| SCHEMBL2716862 | 0.82 | GFPT1 (0.49) | GFPT1SLC7A5CASRGRIK1PTGS1 | |
| SCHEMBL14381155 | 0.81 | KDM4E (0.37) | GFPT1CASR | |
| SCHEMBL19371884 | 0.81 | KDM4E (0.37) | GFPT1CASR | |
| SCHEMBL31524073 | 0.80 | CYP2D6 (0.50) | GFPT1SLC7A5CASRGRIK1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-22 | — | — | US | claimed |
| EP-4658374-A1 | METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | claimed |
| EP-4613761-A9 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| EP-4613761-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4554671-A1 | CYCLIC PEPTIDE INHIBITORS OF IL-23 | JANSSEN Pharmaceutica NV (BE) | 2025-05-21 | — | — | EP | claimed |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-11-21 | — | — | US | claimed |
| WO-2024163643-A1 | METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-08 | — | — | WO | claimed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | claimed |
| CN-113993880-A | Cyclic peptide, cell scaffold material, cell separation material and culture medium | 富士胶片株式会社 | 2022-01-28 | — | — | CN | claimed |
| US-20220024975-A1 | ALPHA-V BETA-6 INTEGRIN LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-01-27 | — | — | US | claimed |
| WO-2020250855-A1 | CYCLIC PEPTIDE, CELL SCAFFOLD MATERIAL, CELL SEPARATION MATERIAL AND CULTURE MEDIUM | 富士フイルム株式会社 | 2020-12-17 | — | — | WO | claimed |
| EP-1976873-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-10-08 | — | — | EP | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | claimed |
| EP-0906099-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | claimed |
| EP-0906099-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-04-07 | — | — | EP | claimed |
| WO-1997036587-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | claimed |
| EP-0783518-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | GFPT1 1805/4885SLC7A5 2674/4885CASR 803/4885 |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | GFPT1 188/4885SLC7A5 801/4885CASR 3247/4885 |
| US-20220024975-A1 | ALPHA-V BETA-6 INTEGRIN LIGANDS AND USES THEREOF | ITGAV, ITGA6, ITGB6 | GFPT1 2870/4885SLC7A5 3803/4885CASR 1250/4885 |
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | IL23R, IL17A, IL36G | GFPT1 4157/4885SLC7A5 1263/4885CASR 831/4885 |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | GFPT1 3717/4885SLC7A5 3470/4885CASR 637/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | GFPT1 4442/4885SLC7A5 1439/4885CASR 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.